DK3582776T3 - Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder - Google Patents
Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder Download PDFInfo
- Publication number
- DK3582776T3 DK3582776T3 DK18754330.1T DK18754330T DK3582776T3 DK 3582776 T3 DK3582776 T3 DK 3582776T3 DK 18754330 T DK18754330 T DK 18754330T DK 3582776 T3 DK3582776 T3 DK 3582776T3
- Authority
- DK
- Denmark
- Prior art keywords
- related methods
- piperidine substituted
- mnk inhibitors
- mnk
- inhibitors
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458671P | 2017-02-14 | 2017-02-14 | |
| PCT/US2018/018022 WO2018152117A1 (en) | 2017-02-14 | 2018-02-13 | Piperidine-substituted mnk inhibitors and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3582776T3 true DK3582776T3 (da) | 2024-01-08 |
Family
ID=63106539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18754330.1T DK3582776T3 (da) | 2017-02-14 | 2018-02-13 | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180228803A1 (da) |
| EP (1) | EP3582776B1 (da) |
| JP (2) | JP2020507588A (da) |
| KR (1) | KR20190117013A (da) |
| CN (1) | CN110719781A (da) |
| AU (2) | AU2018220840A1 (da) |
| BR (1) | BR112019016707A2 (da) |
| CA (1) | CA3053493A1 (da) |
| CL (1) | CL2019002297A1 (da) |
| CO (1) | CO2019009423A2 (da) |
| DK (1) | DK3582776T3 (da) |
| EA (1) | EA201991894A1 (da) |
| ES (1) | ES2969988T3 (da) |
| FI (1) | FI3582776T3 (da) |
| IL (1) | IL268619B (da) |
| MX (1) | MX2019009653A (da) |
| PE (1) | PE20191349A1 (da) |
| PH (1) | PH12019550140A1 (da) |
| SG (1) | SG11201907356SA (da) |
| TW (1) | TWI762579B (da) |
| WO (1) | WO2018152117A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020507588A (ja) | 2017-02-14 | 2020-03-12 | イーフェクター セラピューティクス， インコーポレイテッド | ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法 |
| US11130757B2 (en) | 2018-10-24 | 2021-09-28 | Effector Therapeutics Inc. | Crystalline forms of MNK inhibitors |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| PT4063364T (pt) | 2019-11-18 | 2024-10-30 | Jumbo Drug Bank Co Ltd | Compostos de pirrolotriazina que atuam como inibidor de mnk |
| EP4200296A1 (en) * | 2020-08-20 | 2023-06-28 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| JP2024516885A (ja) | 2021-05-08 | 2024-04-17 | 成都嘉葆薬銀医薬科技有限公司 | ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法 |
| CN114736205B (zh) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备方法 |
| CN114853756B (zh) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备工艺 |
| WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
| CN116425750A (zh) * | 2023-02-10 | 2023-07-14 | 诺沃斯达药业(上海)有限公司 | 一种mnk抑制剂化合物的盐、晶体及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| US7105506B2 (en) | 2001-06-05 | 2006-09-12 | Lilly Icos Llc | Tetracyclic compounds as PDE5-inhibitors |
| ES2359233T3 (es) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular. |
| US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20060281670A1 (en) | 2005-06-10 | 2006-12-14 | Wisconsin Alumni Research Foundation (Warf) | Compositions and methods for modulating angiogenesis |
| JP2009509921A (ja) | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| JP5569956B2 (ja) | 2007-03-16 | 2014-08-13 | ザ スクリプス リサーチ インスティテュート | 接着斑キナーゼのインヒビター |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| EP2219649A2 (en) | 2007-11-22 | 2010-08-25 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| AU2009286734A1 (en) * | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| EP2355819A2 (en) | 2008-11-12 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating a mnk |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| NZ608584A (en) | 2010-10-01 | 2015-07-31 | Bayer Ip Gmbh | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| PE20141404A1 (es) | 2011-12-30 | 2014-10-28 | Hanmi Pharm Ind Co Ltd | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| US20150133426A1 (en) | 2012-05-21 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| EP2917185B1 (en) | 2012-11-09 | 2017-05-10 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
| CA2901527A1 (en) | 2013-02-20 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| TW201605867A (zh) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| AU2015366417A1 (en) | 2014-12-19 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors |
| CN107750167B (zh) | 2015-04-20 | 2021-05-25 | 效应物治疗公司 | 用于治疗癌症和感染的免疫检查点调节剂的抑制剂 |
| MX2018005203A (es) | 2015-10-29 | 2018-07-06 | Effector Therapeutics Inc | Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). |
| JP6892444B2 (ja) | 2015-10-29 | 2021-06-23 | イーフェクター セラピューティクス， インコーポレイテッド | Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬 |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| EP3397774A1 (en) | 2015-12-31 | 2018-11-07 | Effector Therapeutics Inc. | Mnk biomarkers and uses thereof |
| AU2017382830A1 (en) * | 2016-12-19 | 2019-06-13 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof |
| JP2020507588A (ja) | 2017-02-14 | 2020-03-12 | イーフェクター セラピューティクス， インコーポレイテッド | ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法 |
| WO2018218038A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| EP3710053A1 (en) | 2017-11-16 | 2020-09-23 | Novartis AG | Combination therapies |
| WO2019103926A1 (en) | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| US11130757B2 (en) | 2018-10-24 | 2021-09-28 | Effector Therapeutics Inc. | Crystalline forms of MNK inhibitors |
-
2018
- 2018-02-13 JP JP2019543809A patent/JP2020507588A/ja active Pending
- 2018-02-13 BR BR112019016707A patent/BR112019016707A2/pt unknown
- 2018-02-13 ES ES18754330T patent/ES2969988T3/es active Active
- 2018-02-13 SG SG11201907356SA patent/SG11201907356SA/en unknown
- 2018-02-13 WO PCT/US2018/018022 patent/WO2018152117A1/en active Application Filing
- 2018-02-13 CA CA3053493A patent/CA3053493A1/en active Pending
- 2018-02-13 US US15/895,523 patent/US20180228803A1/en not_active Abandoned
- 2018-02-13 MX MX2019009653A patent/MX2019009653A/es unknown
- 2018-02-13 FI FIEP18754330.1T patent/FI3582776T3/fi active
- 2018-02-13 PE PE2019001676A patent/PE20191349A1/es unknown
- 2018-02-13 AU AU2018220840A patent/AU2018220840A1/en not_active Abandoned
- 2018-02-13 EA EA201991894A patent/EA201991894A1/ru unknown
- 2018-02-13 CN CN201880011685.6A patent/CN110719781A/zh active Pending
- 2018-02-13 EP EP18754330.1A patent/EP3582776B1/en active Active
- 2018-02-13 TW TW107105327A patent/TWI762579B/zh active
- 2018-02-13 DK DK18754330.1T patent/DK3582776T3/da active
- 2018-02-13 KR KR1020197026790A patent/KR20190117013A/ko not_active Application Discontinuation
- 2018-12-27 US US16/233,507 patent/US11083727B2/en active Active
-
2019
- 2019-08-09 PH PH12019550140A patent/PH12019550140A1/en unknown
- 2019-08-11 IL IL268619A patent/IL268619B/en unknown
- 2019-08-13 CL CL2019002297A patent/CL2019002297A1/es unknown
- 2019-08-29 CO CONC2019/0009423A patent/CO2019009423A2/es unknown
-
2021
- 2021-08-06 US US17/396,187 patent/US11878015B2/en active Active
-
2022
- 2022-04-29 AU AU2022202864A patent/AU2022202864B2/en active Active
- 2022-09-29 JP JP2022156442A patent/JP2022185050A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009653A (es) | 2019-12-19 |
| US20220096472A1 (en) | 2022-03-31 |
| US11083727B2 (en) | 2021-08-10 |
| PE20191349A1 (es) | 2019-09-30 |
| WO2018152117A1 (en) | 2018-08-23 |
| CL2019002297A1 (es) | 2019-11-08 |
| IL268619A (en) | 2019-10-31 |
| EP3582776A4 (en) | 2020-09-02 |
| EP3582776B1 (en) | 2023-11-08 |
| IL268619B (en) | 2022-05-01 |
| CO2019009423A2 (es) | 2019-09-09 |
| AU2022202864B2 (en) | 2024-06-06 |
| JP2022185050A (ja) | 2022-12-13 |
| EP3582776A1 (en) | 2019-12-25 |
| TWI762579B (zh) | 2022-05-01 |
| PH12019550140A1 (en) | 2020-06-01 |
| AU2018220840A1 (en) | 2019-09-19 |
| AU2022202864A1 (en) | 2022-05-19 |
| TW201835076A (zh) | 2018-10-01 |
| JP2020507588A (ja) | 2020-03-12 |
| US20190275039A1 (en) | 2019-09-12 |
| US20180228803A1 (en) | 2018-08-16 |
| FI3582776T3 (fi) | 2024-01-03 |
| US11878015B2 (en) | 2024-01-23 |
| CA3053493A1 (en) | 2018-08-23 |
| SG11201907356SA (en) | 2019-09-27 |
| EA201991894A1 (ru) | 2020-02-05 |
| BR112019016707A2 (pt) | 2020-04-07 |
| CN110719781A (zh) | 2020-01-21 |
| ES2969988T3 (es) | 2024-05-23 |
| KR20190117013A (ko) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3582776T3 (da) | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder | |
| DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3319428T3 (da) | Herbicid sammensætning omfattende cinmethylin og imazamox | |
| DK3316909T5 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3621694T5 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3368663T3 (da) | Virusfri cellelinjer og fremgangsmåder til opnåelse deraf | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3551787T3 (da) | Elektropoleringsfremgangsmåde og anlæg hertil | |
| DK3177608T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3516160T3 (da) | Brøndanordning og tilhørende fremgangsmåder | |
| DK3729378T3 (da) | Hovedmonteret displayindretning og fremgangsmåde dertil | |
| DK3268374T3 (da) | Kv1.3-inhibitorer og deres medicinske anvendelse | |
| DK3426934T3 (da) | Monteringsholdeanordninger og fremgangsmåder | |
| DK3615502T3 (da) | Terapeutiske forbindelser og fremgangsmåder |